Premium
Neuroprotective effects of pyruvate and piroxicam in animals treated with 1‐methyl‐4‐phenyl‐1, 2, 3, 6 tetrahydropyridine (MPTP)
Author(s) -
Soliman Yousef I,
Mazzio Elizabeth A,
Soliman Karam F
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.707.18
Subject(s) - mptp , piroxicam , pharmacology , neuroprotection , dopaminergic , chemistry , dopamine , toxicity , medicine , endocrinology , alternative medicine , organic chemistry , pathology
MPTP (1‐methyl‐4‐phenyl‐1, 2, 3, 6 tetrahydropyridine) is a prototypical toxin used to induce Parkinsonism in experimental animal models and is known to involve mitochondrial complex I inhibition, oxidative stress and robust gliosis with inflammation. In this study, neuroblastoma N2A cell line was used to investigate the neuroprotective effects of pyruvate and piroxicam. The results demonstrate that pyruvate as well as piroxicam were capable of sparing neuronal damage. In another study to examine the extent to which each of these compounds may prevent the loss of SN dopaminergic neurons induced by administration of MPTP in C57/B6 mice. The administration of pyruvate 150‐mg/kg and piroxicam 20 mg/kg I.P, 3 days pre and post MPTP administration, were effective in reducing the loss of locomotive function, SN tyrosine hydroxylase concentration and attenuating the loss of dopamine. These data suggest that pyruvate, which is a non‐toxic food derived carboxylic acid, may have therapeutic value in the treatment of PD. The data also support previous studies reporting that COX inhibitors attenuated MPTP toxicity in animal models. It was concluded from these study that pyruvate as well as piroxicam may be used in PD prevention and therapy. (Supported by NIH Grant RR03020)